Privia Health Group, Inc. (PRVA)
NASDAQ: PRVA · IEX Real-Time Price · USD
18.17
-0.63 (-3.35%)
At close: Apr 24, 2024, 4:00 PM
18.10
-0.07 (-0.39%)
Pre-market: Apr 25, 2024, 7:07 AM EDT
Privia Health Group Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Privia Health Group stock have an average target of 28.2, with a low estimate of 21 and a high estimate of 41. The average target predicts an increase of 55.20% from the current stock price of 18.17.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PRVA stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 3 |
| Buy | 7 | 8 | 8 | 8 | 6 | 5 |
| Hold | 0 | 0 | 0 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +37.59% | Apr 22, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $41 → $37 | Strong Buy | Maintains | $41 → $37 | +103.63% | Mar 19, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $38 → $30 | Buy | Maintains | $38 → $30 | +65.11% | Mar 6, 2024 |
| Barclays | Barclays | Hold Initiates $22 | Hold | Initiates | $22 | +21.08% | Mar 6, 2024 |
| UBS | UBS | Strong Buy Maintains $31 → $29 | Strong Buy | Maintains | $31 → $29 | +59.60% | Mar 1, 2024 |
Financial Forecast
Revenue This Year
2.90B
from 1.66B
Increased by 74.76%
Revenue Next Year
3.32B
from 2.90B
Increased by 14.60%
EPS This Year
0.25
from 0.19
Increased by 29.99%
EPS Next Year
0.34
from 0.25
Increased by 36.88%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.0B | 3.7B | 4.0B | 3.6B | 4.3B |
| Avg | 2.9B | 3.3B | 3.8B | 3.2B | 3.8B |
| Low | 2.8B | 3.1B | 3.5B | 2.8B | 3.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 83.0% | 27.3% | 20.7% | -5.0% | 36.3% |
| Avg | 74.8% | 14.6% | 13.0% | -15.2% | 18.0% |
| Low | 66.1% | 6.6% | 4.1% | -25.7% | -0.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.35 | 0.42 | 0.72 |
| Avg | 0.25 | 0.34 | 0.45 |
| Low | 0.17 | 0.23 | 0.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 82.4% | 70.1% | 114.3% |
| Avg | 30.0% | 36.9% | 33.4% |
| Low | -12.3% | -8.7% | -1.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.